



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T: 91 80 2808 2808
F: 91 80 2852 3423

CIN: L24234KA1978PLC003417

www.biocon.com

December 12, 2022

To, The Manager BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To, The Manager National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code – 532523	Scrip Symbol – Biocon

Subject: Appointment of Independent Director

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, ('SEBI Listing Regulations') and in continuation to our letter dated November 14, 2022, wherein it was informed that the Board of Directors at its meeting held on Monday, November 14, 2022, had approved the appointment of Mr. Peter Bains as an Additional Director (Category: Non-Executive, Independent Director) of the Company w.e.f. date of activation of DIN and registration in the Independent Director's databank maintained by the Indian Institute of Corporate Affairs (IICA), whichever is later and his appointment as an Independent Director of the Company, not liable to retire by rotation, for a term commencing from the aforesaid date, till the conclusion of 48th Annual General Meeting proposed to be held in the year 2026, subject to approval of the shareholders of the Company.

In this regard, please note that the DIN of Mr. Peter Bains is active and he is also registered with the Independent Director's databank, and accordingly his appointment as an Additional Director is effective from today i.e. December 12, 2022.

Further, the appointment of Mr. Peter Bains as an Independent Director shall commence from December 12, 2022, till the conclusion of 48th Annual General Meeting proposed to be held in the year 2026, subject to approval of the shareholders of the Company.



The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the above information on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

MAYANK
VERMA
Digitally signed
by MAYANK
VERMA
Date: 2022.12.12
19:25:57 +05'30'

Mayank Verma

Company Secretary & Compliance Officer

Membership No: ACS 18776

Brief Profile of Mr. Peter Bains



Mr. Peter Bains, 65 years, holds a bachelor's degree in Science (Combined honours in Zoology and Physiology) from University of Sheffield, United Kingdom. He has Global experience in strategic and operational leadership including at Board, CEO and Senior Corporate levels with an extensive track record of leadership and success in building and companies, businesses, teams and brands over 30 years.

Peter brings in differentiating characteristics with extensive experience in Biopharmaceuticals across business and technology segmentation (Biotech, Vaccines, Branded Generics, Life Sciences, CRO) and geography encompassing both developed and emerging markets.

Presently, Peter is the Non-Executive Director on the Board of Indivior PLC, a UK FTSE listed pharmaceuticals company, MiNA Therapeutics, a privately held UK biotech company and world leader in small activating RNA technology and Apterna, a privately held UK biotech engaged in aptamer discovery. Peter is also Non-Executive Chairman of ILC Therapeutics, a privately held Scottish biotechnology company.

Peter served as CEO and on the Board of Syngene International Limited (Syngene), subsidiary of the Company, for almost 6 years from 2010, and led the company to its successful public listing in 2015. He also served as CEO of Sosei Group, a Japanese listed biopharmaceutical company. Prior to this, Peter worked with GlaxoSmithKline over a period of 23 years, where he held several roles including head of global marketing and senior vice president of commercial development for GSK's International region.